Insmed Sees BRINSUPRI Reaching $7 Billion in Peak Sales, Expects Cash-Flow Positive Year Ahead

Insmed logo with Healthcare background
Image from MarketBeat Media, LLC.

Insmed NASDAQ: INSM expects its bronchiectasis drug BRINSUPRI to generate $1.35 billion to $1.4 billion in its first full year of launch, Chief Executive Officer Will Lewis said, as the company looks to reach more patients and expand its pipeline.

Speaking at the Jefferies Global Healthcare Conference in London, Lewis said BRINSUPRI had surpassed $1 billion in sales. He estimated the drug could eventually reach at least $7 billion in peak sales, excluding international markets and patients who also have chronic obstructive pulmonary disease (COPD) or asthma.

Lewis acknowledged that some of Insmed’s launch-related communications had confused investors, but said the company had beaten and raised guidance each quarter this year. He attributed the drug’s uptake in part to disease education before launch and to patients reporting that they felt better on treatment.

Patient growth and advertising

Insmed estimates that 500,000 people in the United States have bronchiectasis, including 250,000 with two or more exacerbations, Lewis said. The company has put tens of thousands of patients on BRINSUPRI, leaving it roughly 10% penetrated in its initial target population, he said.

Lewis said the company’s last publicly disclosed insurance approval rate for the drug was 90% and that patient persistence had exceeded both Insmed’s own expectations and a benchmark provided by McKinsey before launch. He did not disclose a current persistence rate.

Patients who discontinue typically do so within the first six to eight weeks, after which the rate of drop-off slows, he said. Lewis added that some patients stop because they do not feel better immediately, although the company cannot promote delayed symptom improvement because it is not in the drug’s label.

Insmed plans to begin its first U.S. direct-to-consumer advertising campaign for BRINSUPRI in about a week, Lewis said. He expects the campaign to accelerate new patient starts, with a potential revenue contribution appearing toward the end of the first quarter or in the second quarter. He forecast that quarterly new starts could rise by a few hundred next year.

Additional markets and ARIKAYCE

Lewis called the opportunity to identify bronchiectasis in patients who also have COPD or asthma the company’s biggest potential value driver over the next three to five years. He estimated that roughly 20% of the 32 million U.S. patients with asthma or COPD may also have undiagnosed bronchiectasis, though only a portion may be highly symptomatic and potentially benefit from BRINSUPRI.

Insmed is reviewing CT scans of COPD and asthma patients and hopes to publish findings next year to better document the potential market, Lewis said. The company has a separate group working on the opportunity.

In Japan, BRINSUPRI launched recently, and Insmed plans to add 50 sales representatives to its team there, with the additions expected to take effect by the middle of next year. Lewis also pointed to potential frontline expansion of ARIKAYCE, which he said would increase its addressable market sevenfold. He said the U.S. regulatory decision date is at the end of January and that the company expects a Japanese frontline decision in the first half of next year.

Pipeline and profitability outlook

Lewis said Insmed is running four Phase 3 studies of TPIP and has clinical data from earlier studies for three of the programs. He said enrollment in the pulmonary hypertension associated with interstitial lung disease study was six months ahead of schedule.

For pulmonary arterial hypertension, Lewis cited improvements reported in a Phase 2 open-label extension, including a 55-meter increase in the six-minute walk measure and a 35% reduction in pulmonary vascular resistance. He said another year of data is expected next year.

Insmed also expects data next year from its gene therapy program for Duchenne muscular dystrophy. If results are strong, the company would move directly into a pivotal study aimed at accelerated approval, Lewis said. It also plans to begin a Phase 2 study of INS1148 in idiopathic pulmonary fibrosis next year.

Lewis said he expects Insmed to become cash-flow positive next year while continuing to invest in its pipeline. He projected more than 20% compound annual revenue growth over the next decade from a base of nearly $2 billion this year, though that forecast depends on future performance across multiple drugs and potential indications.

About Insmed (NASDAQ:INSM)

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing treatments for serious diseases, including respiratory and rare conditions. The company is based in Bridgewater, New Jersey, and is led by President and Chief Executive Officer William H. Lewis Jr. Its commercial products include ARIKAYCE, an inhaled amikacin treatment for certain adults with refractory Mycobacterium avium complex lung disease, and BRINSUPRI (brensocatib), an oral treatment for non-cystic fibrosis bronchiectasis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Insmed Right Now?

Before you consider Insmed, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.

While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

 The Best Nuclear Energy Stocks to Buy Cover

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines